Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells

被引:15
|
作者
Wang, Kaifang [3 ,4 ]
Cai, Rong [1 ,2 ]
Fei, Shuting [1 ,2 ]
Chen, Xuzheng [2 ]
Feng, Sisi [1 ,2 ]
Zhang, Lulu [1 ,2 ]
Liu, Hui [1 ]
Zhang, Zhiguang [1 ,2 ]
Song, Jun [1 ,2 ,5 ]
Zhou, Ruixiang [1 ,2 ,5 ]
机构
[1] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Peoples R China
[2] Fujian Med Univ, Minist Educ, Key Lab Gastrointestinal Canc, Fuzhou, Peoples R China
[3] Shenzhen Univ, Sch Dent, Med Sch, Shenzhen, Peoples R China
[4] Hong Kong Baptist Univ, Fac Sci, Dept Biol, Hong kong, Peoples R China
[5] Fujian Med Univ, Sch Basic Med Sci, Fuzhou 350122, Fujian, Peoples R China
关键词
Melatonin (MLT); Gastric cancer; Exosomes; Macrophages; Tumor microenvironment; PATHWAY;
D O I
10.1016/j.mce.2023.111917
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Melatonin (MLT) is a hormone with potential anti-tumor properties, but the molecular mechanisms remain unclear. The present study aimed to explore the effect of MLT on exosomes derived from gastric cancer cells, with the goal of gaining insight into its anti-tumor activity. Results from in vitro experiments showed that MLT was able to enhance the anti-tumor activity of macrophages that had been suppressed by exosomes from gastric cancer cells. This effect was achieved through regulation of the levels of PD-L1 in macrophages via modulation of the associated microRNAs in the cancer-derived exosomes. Furthermore, MLT treatment increased the secretion of TNF-alpha and CXCL10 by the macrophages. Besides, MLT treatment of gastric cancer cells led to the production of exosomes that promoted the recruitment of CD8+ T cells to the tumor site, resulting in inhibition of tumor growth. Collectively, these results provide evidence for the modulation of the tumor immune microenvironment by MLT through regulation of exosomes derived from gastric cancer cells, suggesting a potential role for MLT in novel anti-tumor immunotherapies.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Targeting Macrophages with CAR-T Cells Delays Solid Tumor Progression and Enhances Anti-Tumor Immunity
    Sanchez-Paulete, Alfonso R.
    Mateus-Tique, Jaime
    Mollaoglu, Gurkan
    Nielsen, Sebastian R.
    Marks, Adam
    Lakshmi, Ashwitha
    Pia, Luisanna
    Baccarini, Alessia
    Merad, Miriam
    Brown, Brian D.
    MOLECULAR THERAPY, 2022, 30 (04) : 317 - 317
  • [22] Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
    Poggio, Mauro
    Hu, Tianyi
    Pai, Chien-Chun
    Chu, Brandon
    Belair, Cassandra D.
    Chang, Anthony
    Montabana, Elizabeth
    Lang, Ursula E.
    Fu, Qi
    Fong, Lawrence
    Blelloch, Robert
    CELL, 2019, 177 (02) : 414 - +
  • [23] Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
    Munoz, Luis Enrique
    Huang, Lei
    Bommireddy, Ramireddy
    Sharma, Richa
    Monterroza, Lenore
    Guin, Rohini N.
    Samaranayake, Sarah G.
    Pack, Christopher D.
    Ramachandiran, Sampath
    Reddy, Shaker J. C.
    Shanmugam, Mala
    Selvaraj, Periasamy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [24] Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
    Chengyu Shi
    Ying Wang
    Minjie Wu
    Yu Chen
    Fangzhou Liu
    Zheyuan Shen
    Yiran Wang
    Shaofang Xie
    Yingying Shen
    Lingjie Sang
    Zhen Zhang
    Zerui Gao
    Luojia Yang
    Lei Qu
    Zuozhen Yang
    Xinyu He
    Yu Guo
    Chenghao Pan
    Jinxin Che
    Huaiqiang Ju
    Jian Liu
    Zhijian Cai
    Qingfeng Yan
    Luyang Yu
    Liangjing Wang
    Xiaowu Dong
    Pinglong Xu
    Jianzhong Shao
    Yang Liu
    Xu Li
    Wenqi Wang
    Ruhong Zhou
    Tianhua Zhou
    Aifu Lin
    Nature Communications, 15 (1)
  • [25] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
    Weixin Liu
    Ruibao Liu
    Ronghui Yuan
    Xing Wang
    Molecular Biotechnology, 2021, 63 : 1268 - 1279
  • [26] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
    Liu, Weixin
    Liu, Ruibao
    Yuan, Ronghui
    Wang, Xing
    MOLECULAR BIOTECHNOLOGY, 2021, 63 (12) : 1268 - 1279
  • [27] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
    Daisuke Umezu
    Nana Okada
    Yukimi Sakoda
    Keishi Adachi
    Toshiyasu Ojima
    Hiroki Yamaue
    Masatoshi Eto
    Koji Tamada
    Cancer Immunology, Immunotherapy, 2019, 68 : 201 - 211
  • [28] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
    Umezu, Daisuke
    Okada, Nana
    Sakoda, Yukimi
    Adachi, Keishi
    Ojima, Toshiyasu
    Yamaue, Hiroki
    Eto, Masatoshi
    Tamada, Koji
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 201 - 211
  • [29] Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment
    Li, Jie
    Cao, Peiyu
    Chen, Yuxin
    Wang, Junqi
    Sun, Xiaolei
    Chen, Renfu
    Wang, Gang
    Hou, Jianquan
    EXPERIMENTAL CELL RESEARCH, 2022, 417 (01)
  • [30] A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
    Pan, Jiayi
    Zeng, Wuyi
    Jia, Jiangtao
    Shi, Yi
    Wang, Danni
    Dong, Jun
    Fang, Zixuan
    He, Jiashan
    Yang, Xinyu
    Zhang, Rong
    He, Menghua
    Huang, Maoping
    Fu, Bishi
    Zhong, Bei
    Liu, Hui
    VACCINES, 2022, 10 (07)